Hotline 03-84081983
Facebook Instagram Youtube
  • About
  • Research
  • Product
  • Medical Use
  • AlGraft

AlGraft

What is CelltiSS?

ALGRAFT is an Allogenic Bilayer Tissue Engineered Human Skin (TEHS) substitute to treat and manage wounds and major skin loss. 

ALGRAFT  is derived from young, healthy donors that went through extensive screening prior to extraction, amplification and construction as TEHS. It comprises of fibroblasts and keratinocytes cells that mimics 90% human skin morphology and functions.

​ALGRAFT is beneficial for early coverage of wounds to prevent infection, contracture and promoting healing by stimulating the patient’s skin formation.
The conditioned media is obtained from a cell culture collected at 80-90% confluency during the mitotic phase of cell replication for maximum production. It is indicated for wound bed preparation in full-thickness skin loss due to burns, trauma, pressure ulcers, or diabetic ulcers.
ALGRAFT can be constructed from a single donor skin tissue such as facelift, abdominoplasty and neonatal foreskin from circumcision. Once lab personnel receives tissue and blood samples from donor biopsy, serum and plasma, the tissue is then processed.

The skin layers are separated and digested by using specific enzymes, leaving the fibroblasts and keratinocytes. Human Derived Plasma (HDP) is used as the biomaterial/ scaffold for constructing the skin graft composite. Together with the keratinocyte and fibroblast layers, it creates the 3 – Dimensional structure providing ​ALGRAFT the ideal bilayer skin substitute for significant skin loss.

ALGRAFT is a perfect alternative material for the wound care industry whereby it is useful in the treatment of:

    • Huge skin loss due to major burns
    • Non-healing or recurring ulcers
    • Full thickness skin loss due to trauma  
    • Skin loss due to other medical causes

ADVANTAGES OF ALGRAFT

Reduces cell transplantation and complications.
No biopsy required.
Minimal risk of rejection.
Readily available.

WHY CHOOSE ALGRAFT

    • Double-layer characteristic in ​ALGRAFT means it mimics the native skin layer of the epidermis.
    • Functions as a temporary coverage of wound.
    • Able to cover a large wound without the need to harvest from patient own tissue
    • Able to restore the barrier function of damaged or burned skin.
    • Has the ability to secrete growth factors, enzymes and biochemical to mimic the physiological activity of the skin, hence promote rapid wound healing.

COMPARISON OF ALGRAFT WITH OTHER SKIN SUBSTITUTES

CHARACTERISTICS
ALGRAFT
OTHER PRODUCTS
Source of Substances
Human
​Animal
​Ingredients
Donor fibroblasts, keratinocytes and fibrin
​Bovine tendon collagen, glycosaminoglycan and silicone
HDP Biomaterial
Yes
No
​Scaffold
Donor’s blood
Other sources
​No of Surgery
​One
Two
SSG Procedure
No
Yes
​Associated with Growth Factors
Yes
No
​Preservation & Reculture of cells
Yes
No

ALGRAFT CASE STUDY

Age and comorbidity
​39 years old male/ diabetics on insulin.
Wound etiology
Gustillo Anderson 3A open compound fracture of right leg.
Outcome 
​Patient underwent ALGraft implantation on 19/8/2020.  The wound is completely closed after 8 weeks for a smaller wound (wound B). The more significant wound (wound A) 80% covered by 8 weeks.

INDICATION FOR ALGRAFT

ALGRAFT is used in a wide variety of massive skin tissue loss due to trauma, burning, chronic and diabetic ulcers.​
 

PREPARATION AND DELIVERY

    • Preparation of ALGRAFT takes  7 working days.
    • ALGRAFT is delivered in a 10 x 10 cm² construct inside a sterile plastic Omni tray.
    • ALGRAFT is delivered and stored inside a cooler box to maintain the temperature between +4 to +8 Celsius.
    • ALGRAFT must be used within 24 hours after delivery.
    • ALGRAFT handling must be strictly aseptic.

SHELF LIFE

ALGRAFT must be used within 3 days from final construct date

Publication

1. Ishak, M. F., Manira, M., Ng, M. H., Khairul, B., Gargy, L., Aminuddin, B. S., & Ruszymah, B. H. (2019). Long Term Effect of Cryopreservation on Primary Human Skin Cells. SAINS MALAYSIANA, 48(1), 137-144.

2. Idrus, R. B. H., Rameli, M. A. B. P., Cheong, L. K., Xian, L. J., Hui, C. K., Latiff, M. B. A., & Saim, A. B. (2014). Allogeneic bilayered tissue-engineered skin promotes full-thickness wound healing in ovine model.

CELL TISSUE TECHNOLOGY SDN BHD

Malaysia's FIRST Tissue Engineering Firm

Established in 2010, Cell Tissue is a Malaysian advanced medical technologybased company, a spin-off of the National University of Malaysia (UKM), one of the country’s leading universities and research institutes.

Cell Tissue is known as Malaysia’s FIRST Tissue Engineering Firm, awarded by the prestigious Malaysian Book of Records in 2016, operated in a certified Current Good Manufacturing Practice (cGMP) laboratory following PIC/S standards by the National Pharmaceutical Regulatory Agency (NPRA), a division of the Ministry of Health Malaysia.

CytoLife & Celllora (1)

FEATURED LINKS

CONNECT WITH US

Facebook Jki-instagram-1-light Youtube

Proudly powered by CTTSB © 2010-2024 Cell Tissue Technology Sdn Bhd, a Universiti Kebangsaan Malaysia spin-off Company. – All rights reserved.